Introduction of 123039-93-0 :
Dihydrexidine (DAR-0100) is a high potent, selective and full efficacy D1-like dopamine receptor (D1/D5) agonist with an IC50 of 10 nM for D1 receptor. Dihydrexidine exhibits potent antiparkinsonian activity[1][2][3][4]. IC50 & Target: IC50: 10 nM (D1 dopamine receptor), D5 dopamine receptor, 660 nM (D1 dopamine receptor)[1] In Vivo: Dihydrexidine has poor oral bioavailability and a relatively short half-life of 1 to 2 h[3].
Dihydrexidine (3 mg/kg; i.p.) produces prominent dopamine D1 receptor agonist effects in vivo[4].